HomeAbout SPIFor PatientsFor PhysiciansSPI DoctorsDirections206.215.2480

Clinical Training CoursesTechnical AssistanceBrachytherapy ConferencePCa Commentary



PCa Commentary
 

"Predicting The Outcome Of Salvage Radiation Therapy For Recurrent Prostate Cancer After Radical Prostatectomy, (JCO, May 2007) (July 2007)

 This very useful and authoritative resource by Stephenson and 19 other well known prostate cancer experts (including Dr. Dan Lin, UW) is based on follow-up of 1540 patients from 17 North American tertiary referral centers. The article provides a nomogram giving 6-year progression free probabilities that integrate the weighted contribution of 11 standard clinical variables. The overall message is now well recognized: the earliest institution of salvage radiation therapy (SRT) after established PSA recurrence yields the best outcome. "Before SRT, all patients had a PSA level of 0.2 ng/mL or higher at least six weeks after RP followed by another higher value, or a single PSA of 0.5 ng/mL or higher." 

Regarding the morbidity of SRT: "Mild to moderate acute rectal and genitourinary toxicity is seen in the majority of patients, but the reported incidence of acute grade 3 or 4 complications is less than 4%. Late grade 1 to 2 rectal and genitourinary toxicity are reported in 5% to 20% of patients, and late grade 3 toxicity is less than 4%."

An accompanying graph plots the proportion of men free of progression against the time in months from salvage radiotherapy according to four PSA ranges - 0.50 ng/mL or less; 0.51 to 1.0; 1.01 to 1.5, and more than 1.50. The proportion free of progression at 6 years associated with those ranges were: 48%; 40%; 28%; and 18% respectively. But the real value of their analysis lies in the nomogram which allows individualization of probable outcome by integrating a patient's values for the 11 parameters entered onto a continuous variable scale. The authors note that salvage XRT is conventionally recommended to patients estimated to be at low-risk for recurrence, but "Our study demonstrates that select patients with a short PSADT or Gleason grade 8 to 10 cancer may also benefit from SRT.

Dr. Kattan said that this nomogram will be soon be available on-line at "www.nomograms.org."

« Back to Article List


(c) 2007 Seattle Prostate Institute -  All rights reserved.